Prosecution Insights
Prosecution Insights
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEAGU, IRINA | 1 | 46.8% | +57.4% |
| ISMAIL, REHANA | 1 | 77.3% | +32.8% |
| WRIGHT, ERIC BRANDON | 1 | — | — |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.7% |
| HAVLIN, ROBERT H | 1 | 51.6% | +27.9% |
| BARRERA, JUAN C | 1 | 63.2% | +35.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559512 | AAV VIRION ENCODING NEUROTROPHIC FACTOR AND USES THEREOF | VIVLEMORE, TRACY ANN | — |
| 17829286 | NASAL SPRAY GUIDE | BARRERA, JUAN C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18437748 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | ISMAIL, REHANA | 70d |
| 18825758 | METHODS OF TREATING OCULAR CONDITIONS | NEAGU, IRINA | — |
| 18049815 | LOCAL ADMINISTRATION OF NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS FOR THE INHIBITION OF CORONAVIRUS INFECTIONS | HAVLIN, ROBERT H | — |
| 17829286 | NASAL SPRAY GUIDE | BARRERA, JUAN C | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1632 | 1 |
| 1638 | 1 |
| 1626 | 1 |
| 3752 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18825758 | METHODS OF TREATING OCULAR CONDITIONS | NEAGU, IRINA | — | DP | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18437748 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | ISMAIL, REHANA | 1625 | DPOther | Non-Final OA | 70d | Pending | Feb 09, 2024 |
| 18559518 | CO-THERAPY WITH VECTOR AND NICOTINIC AGONIST | WRIGHT, ERIC BRANDON | 1632 | §102§103DP | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18559512 | AAV VIRION ENCODING NEUROTROPHIC FACTOR AND USES THEREOF | VIVLEMORE, TRACY ANN | 1638 | §102§103§112 | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18049815 | LOCAL ADMINISTRATION OF NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS FOR THE INHIBITION OF CORONAVIRUS INFECTIONS | HAVLIN, ROBERT H | 1626 | §103 | Non-Final OA | — | Pending | Oct 26, 2022 |
| 17829286 | NASAL SPRAY GUIDE | BARRERA, JUAN C | 3752 | §103§112 | Final Rejection | — | Pending | May 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial